David Newman, GlaxoSmithKline
S
David Newman
Senior Product Director, Tykerb, GlaxoSmithKline
NOTED FOR: Launch of oncology treatment Tykerb
EXCEEDED RESULTS: Treated 5,500 patients
On what motivates him to succeed:
We think we have it tough. But that's nothing compared to fighting breast cancer. These women help us put our work in perspective, and give us a sense of mission to not necessarily sell Tykerb, but instead make sure every patient gets its benefit of efficacy.
David Newman
In a therapeutic area like oncology, you have a chance to make a real difference. That focus is what keeps me motivated day in and day out.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
